Danaher (NYSE:DHR) Given New $250.00 Price Target at Barclays

Key Points

• Barclays raised its price target for Danaher from $225.00 to $250.00, indicating a potential upside of 13.06% from the stock's previous close.
• The company's stock has received a consensus rating of "Moderate Buy," with an average target price of $246.00 based on ratings from seventeen analysts.
• Danaher reported earnings of $1.89 EPS for the last quarter, surpassing analyst estimates and reflecting a year-over-year revenue increase of 4.4%.

Danaher (NYSE:DHR - Get Free Report) had its price objective raised by equities researchers at Barclays from $225.00 to $250.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the conglomerate's stock. Barclays's target price points to a potential upside of 13.06% from the stock's previous close.

Other equities research analysts have also issued reports about the company. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Guggenheim restated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on Danaher in a research note on Tuesday, September 2nd. Rothschild Redb lowered Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 8th. Finally, Bank of America dropped their price target on Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research note on Monday, September 22nd. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $246.00.

Danaher Stock Performance

Danaher stock opened at $221.13 on Wednesday. The firm has a market capitalization of $158.34 billion, a P/E ratio of 47.05, a PEG ratio of 3.01 and a beta of 0.77. The stock has a fifty day moving average price of $202.07 and a 200 day moving average price of $197.59. Danaher has a 52 week low of $171.00 and a 52 week high of $269.24. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher will post 7.63 earnings per share for the current year.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.20% of the company's stock.

Institutional Investors Weigh In On Danaher

A number of hedge funds have recently bought and sold shares of DHR. GHP Investment Advisors Inc. grew its stake in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. WFA of San Diego LLC acquired a new stake in Danaher during the 2nd quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new stake in Danaher during the 2nd quarter valued at approximately $27,000. TruNorth Capital Management LLC acquired a new stake in Danaher during the 3rd quarter valued at approximately $28,000. Finally, Sierra Ocean LLC lifted its holdings in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.